Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen’s Risperdal Consta shown to reduce hospitalisation risk

Janssen’s Risperdal Consta shown to reduce hospitalisation risk

1st April 2011

Janssen has published new clinical data that demonstrates the benefits of the schizophrenia drug Risperdal Consta in lowering the risk of hospitalisation among patients.

The treatment was involved in a 12-month study conducted by the French Cohort for the General Study of Schizophrenia, which aimed to evaluate the impact of long-acting injectable antipsychotic drugs on hospitalisation rates, compared to other antipsychotic treatments.

It was found that Janssen's therapy cut the risk of hospitalisation by 34 percent compared to any other treatment featured in the 1,859-patient trial.

According to Janssen, this represents a significant finding, as relapses and returns to hospital among schizophrenia sufferers can worsen their condition and impact their quality of life, as well as increasing the cost of care.

Dr Lupe Martinez, medical affairs director for Janssen in Europe, the Middle East and Africa, said: "This data supports the important role of antipsychotic medication to help keep a person's symptoms under control and keep their lives stabilised."

Earlier this month, Janssen was granted European regulatory approval for a new schizophrenia treatment called Xeplion, based on positive data from clinical trials.ADNFCR-8000103-ID-800483913-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.